Paul Mitchell

NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer

Jose Luis Leal, Geoffrey Peters, Marcin Szaumkessel, Trishe Leong, Khashayar Asadi, Gareth Rivalland, Hongdo Do, Clare Senko, Paul L Mitchell, Chai Zi Quing, Alexander Dobrovic, Bibhusal Thapa, Thomas John

Journal article  |  2020  |  Lung Cancer

OBJECTIVES: Gene rearrangements involving NTRK1, NTRK2, NTRK3, ROS1 and ALK have been identified in many types of cancer, includin..

Credentialing of vertebral stereotactic ablative body radiotherapy in a multi-centre trial

Nicholas Hardcastle, Tomas Kron, Olivia Cook, Joerg Lehmann, Paul LR Mitchell, Shankar Siva

Journal article  |  2020  |  Physica Medica

PURPOSE/OBJECTIVE: Stereotactic ablative body radiotherapy (SABR) in multi-centre trials requires rigorous quality assurance to en..

Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report

Ashray Gunjur, Geoff Chong, Adeline Lim, Eddie Lau, Paul Mitchell, Thomas John, Surein Arulananda

Journal article  |  2020  |  Clinical Lung Cancer

A Malignant Neoplasm From the Jejunum With a MALAT1-GLI1 Fusion and 26-Year Survival History

Owen William John Prall, Christopher Robert Edward McEvoy, David John Byrne, Amir Iravani, Judy Browning, David Yew-Huong Choong, Bhargavi Yellapu, Sophie O'Haire, Kortnye Smith, Stephen James Luen, Paul Leslie Ross Mitchell, Jayesh Desai, Stephen Bernard Fox, Andrew Fellowes, Huiling Xu

Journal article  |  2020  |  International Journal of Surgical Pathology

The transcription factor GLI1 is a critical effector of the sonic hedgehog pathway. Gene fusions that activate GLI1 have recently ..

Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease

Surein Arulananda, Hongdo Do, Gareth Rivalland, Zoe Loh, Ashan Musafer, Eddie Lau, Paul Mitchell, Alexander Dobrovic, Thomas John

Journal article  |  2019  |  Journal of Thoracic Disease

Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort

Gareth Rivalland, Paul Mitchell, Carmel Murone, Khashayer Asadi, Adrienne L Morey, Maud Starmans, Paul C Boutros, Marzena Walkiewicz, Benjamin Solomon, Gavin Wright, Simon Knight, Thomas John

Journal article  |  2019  |  Translational Lung Cancer Research

The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.

Shengxiang Ren, Qinrui Tian, Nadav Amar, Hui Yu, Christopher J Rivard, Charles Caldwell, Terry L Ng, Megan Tu, Yiwei Liu, Dexiang Gao, Kim Ellison, Kenichi Suda, Leslie Rozeboom, Gareth Rivalland, Paul Mitchell, Caicun Zhou, Fred R Hirsch

Journal article  |  2018  |  Lung Cancer

BACKGROUND: Herpes Virus Entry Mediator (HVEM) is an important immune checkpoint in cancer recognition. HVEM expressed on tumor ce..

NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy (SABR) in advanced non-small cell lung cancer (NSCLC), progressing after first- or second-line chemotherapy

Paul Mitchell, Shankar Siva, Antony Mersiades, Ken O'Byrne, Sarah Chinchen, Chris Brown, Sonia Yip, Martin R Stockler

Conference Proceedings  |  2018  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Impact of Incidence and Progression of Diabetic Retinopathy on Vision-Specific Functioning

Preeti Gupta, Alfred Tau Liang Gan, Ryan Eyn Kidd Man, Eva K Fenwick, Neelam Kumari, Gavin Tan, Paul Mitchell, Charumathi Sabanayagam, Tien Yin Wong, Ching-Yu Cheng, Ecosse L Lamoureux

Journal article  |  2018  |  Ophthalmology

BRAF Mutations-A Good News Story for Immune Checkpoint Inhibitors in Oncogene-Addicted NSCLC?

Surein Arulananda, Paul Mitchell

Journal article  |  2018  |  Journal of Thoracic Oncology